Incretin‐based therapies, particularly GLP‐1/GIP receptor agonists, have demonstrated promising effects by addressing several pathological processes, including oxidative stress, inflammation, misfolded protein aggregation, and insulin resistance. Here, GLP1R is linked to Insulin resistance.